# A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

> **NCT05590572** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 148 (estimated)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** Sulfatinib
- **DRUG:** Etoposide
- **DRUG:** Isophosphamide

## Key facts

- **NCT ID:** NCT05590572
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2022-10-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05590572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05590572, "A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05590572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*